Immunic to participate in scientific and investor conferences in june

New york , may 30, 2023 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in june: may 31-june 3: consortium of multiple sclerosis centers (cmsc) annual meeting 2023. robert j. fox, md, staff neurologist, mellen center for multiple sclerosis, vice-chair for research, neurologic institute, cleveland clinic, cleveland, ohio, will present data from the open-label extension part of immunic's phase 2 emphasis trial of vidofludimus calcium (imu-838) in relapsing-remitting multiple sclerosis at this conference in aurora, colorado.
IMUX Ratings Summary
IMUX Quant Ranking